No results for ‘’
Vivimed Labs Ltd
₹6.72
(4.19%)
Sun, 31 May 2026, 07:23 pm
Health Technology
Pharmaceuticals: Major
24.5KVivimed Labs EV/EBITDA Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 17.42 | 11.79 | 5.30 | 2.03 | 4.48 | 6.27 | 10.33 | 5.38 | 4.32 | 8.27 | 8.30 | 4.15 | 7.62 | 3.51 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price to book ratio | 3.37 | 1.79 | 1 | 0.38 | 0.98 | 1.36 | 1.65 | 1.01 | 0.58 | 1.20 | 1.29 | 1.17 | 0.65 | 0.20 | 0.07 | 0.30 | 0.33 | 1.40 | 0 | 0 |
| Price to sales ratio | 2.13 | 1.20 | 0.48 | 0.14 | 0.40 | 0.74 | 0.98 | 0.41 | 0.21 | 0.43 | 0.52 | 0.61 | 0.50 | 0.15 | 0.06 | 0.15 | 0.50 | 0.30 | 0.27 | 0 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 2.52 | 29.47 | 38.83 | 1560 | 0 | 7.12 | 6.08 | 7.96 | 0 | 0.57 | 2.92 | 0.26 | 0 | 0 | 0 | 0 |
| Enterprise value | 1.71B | 2.12B | 1.86B | 3.23B | 3.69B | 6.03B | 13.43B | 11.55B | 12.27B | 16.4B | 16.2B | 18.44B | 16.56B | 10.61B | 9.52B | 4.51B | 4.72B | 4.33B | 4.17B | 0 |
| Enterprise value to EBITDA ratio | 11.38 | 7.85 | 6.29 | 6.91 | 5.80 | 6.91 | 10.31 | 6.39 | 6.67 | 7.41 | 7.27 | 4.57 | 8.48 | 6.20 | 53.36 | 7.33 | 0 | 0 | 0 | 0 |
| Debt to equity ratio | 0.31 | 0.82 | 1.38 | 2.93 | 1.62 | 1.56 | 1.26 | 1.31 | 1.63 | 1.80 | 1.53 | 1.38 | 0.67 | 1.01 | 1.13 | 0.75 | 0.99 | 9.67 | 0 | 0 |
| Return on equity % | 0 | 23.22 | 20.74 | 20.65 | 25.07 | 28.59 | 18.81 | 17 | 12.42 | 12.88 | 14.63 | 32.44 | 7.99 | 5.29 | -12.27 | -11.35 | -17 | -162.76 | -267.63 | 0 |
Vivimed Labs Ltd Enterprise Value to EBITDA Ratio
The Vivimed Labs Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Vivimed Labs Ltd's valuation, profitability, and overall financial performance. Tracking the Vivimed Labs Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Vivimed Labs Ltd (NSE: VIVIMEDLAB, BSE: 532660) is currently trading at ₹6.72, with a market capitalization of ₹548.06M. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Vivimed Labs Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Vivimed Labs Ltd Enterprise Value to EBITDA Ratio Current Value
The current Vivimed Labs Ltd Enterprise Value to EBITDA Ratio stands at 0.
The Vivimed Labs Ltd Enterprise Value to EBITDA Ratio remains stable, indicating consistent financial performance.
Vivimed Labs Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Vivimed Labs Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 0
- 2023: 0
- 2022: 0
- 2021: 0
- 2020: 7.33
The decline in Vivimed Labs Ltd Enterprise Value to EBITDA Ratio indicates improving financial efficiency or better earnings growth.
What Vivimed Labs Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Vivimed Labs Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Vivimed Labs Ltd.
Vivimed Labs Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Vivimed Labs Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Vivimed Labs Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Vivimed Labs Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.